Innovative Study Design

Learn more

Clinical Trials Execution

Learn more

Data Analysis Center

Learn more

Event Adjudication

Learn more

HCRI designs and runs clinical trials with world-class academic researchers and industry sponsors. We combine the logistical capabilities of a contract research organization with world-class academic scientific leadership.

We have a proven track record in cardiology, central nervous system, and pulmonology, and our research and publications show it.

Comparison of Ischemic and Bleeding Events after Drug-Eluting Stents or Bare Metal Stents in Subject Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT) Study

DAPT Trial Secondary Analysis highlighting whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES as well as whether the optimal duration of DAPT therapy differs for BMS and DES

Blood Clot and Heart Attack Risk After Coronary Stent Treatment Reduced with Continuation of Dual Antiplatelet Therapy Beyond One Year in DAPT Study Findings

The Harvard Clinical Research Institute (HCRI) announced today results of the DAPT Study, a major international study that investigated the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following coronary stent implantation.

Dr Alex Turchin accepted as fellow to ACMI

Congratulations to HCRI faculty member Dr. Alex Turchin, who was recently accepted as a fellow in the American College of Medical Informatics (ACMI).

MEDTRONIC COREVALVE DATA DEMONSTRATE FAVORABLE COST EFFECTIVENESS COMPARED TO OPEN-HEART SURGERY IN HIGH RISK PATIENTS

Cost Effectiveness of Self-Expanding Valve Driven by Improved Quality of Life Benefit and Superior One-Year Survival Rates over Surgical Aortic Valve Replacement. WASHINGTON, D.C., and MINNEAPOLIS – Sept. 13, 2014 – In the first-ever in-trial cost effectiveness analysis of transcatheter aortic valve replacement (TAVR) for patients at high risk for surgery, investigators today revealed new data demonstrating the cost effectiveness of the CoreValve® System from Medtronic, Inc. (NYSE: MDT) for high risk patients with severe aortic stenosis. The economic analysis used data from the CoreValve U.S. Pivotal Trial’s study of high risk patients, which is the only head-to-head study to show the superiority of TAVR to traditional surgical aortic valve replacement (SAVR) at one year. The new data were presented during a late-breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2014.

ODYSSEY COMBO II - Investigational agent outshines ezetimibe for lowering cholesterol

BARCELONA, Spain – Sunday 31 August: The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

A new study from HCRI highlights the importance of post market surveillance stent studies to depict safety signals. Postmarket surveillance of zotarolimus-eluting stents shows similar efficacy compared with premarket studies despite differences in patient populations but finds higher risk of myocardial infarction (MI), according to a paper published online June 9, 2014, in the American Journal of Cardiology.